CXCR4 and acute myeloid leukemia: In addition, CXCR4 is highly expressed in around 50% of AML patients [12,13,14,15,16] and its overexpression correlates with a poor prognosis, which suggests that CXCR4 is an AML potential therapeutic target [12,17,18,19].